Related Experiment Video
Updated: May 8, 2026
05:52
Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
CyclinD1, a prominent prognostic marker for endometrial diseases
1Department of Pathology, Shandong University School of Medicine, 44#, Wenhua Xi Road, 250012 Jinan, Shandong, People's Republic of China. ztguo@sdu.edu.cn.
Diagnostic Pathology
|August 17, 2013
Summary
Cyclin D1 is overexpressed in endometrial hyperplasia and carcinoma, indicating a poor prognosis. While a potential prognostic marker, it has limited ability to differentiate benign from malignant endometrial lesions.
Area of Science:
- Gynecologic Pathology
- Molecular Oncology
- Cancer Biomarkers
Background:
- Cyclin D1's role in endometrial carcinogenesis is suggested but not well-defined in hyperplasia.
- Understanding Cyclin D1 expression is crucial for identifying potential diagnostic and prognostic markers in endometrial lesions.
Purpose of the Study:
- To investigate the relationship between Cyclin D1 expression and clinic-pathological variables in endometrial lesions.
- To explore Cyclin D1 as a potential diagnostic and prognostic marker for endometrial cancer.
Main Methods:
- Immunohistochemical analysis (IHC) of Cyclin D1 expression in 201 endometrial samples.
- Samples included simple hyperplasia, atypical complex hyperplasia (ACH), endometrioid carcinoma, endometrial serous carcinoma (ESC), and clear cell carcinoma (CCC).
- Follow-up study to assess patient prognosis.
Main Results:
- Cyclin D1 was significantly overexpressed in ACH, endometrioid carcinoma, and clear cell carcinoma.
- High Cyclin D1 expression correlated with metastasis and predicted a poor prognosis (p < 0.05).
- Cyclin D1 expression was identified as a risk marker for overall survival, similar to metastasis.
Conclusions:
- Cyclin D1 shows promise as a prognostic marker for endometrial carcinoma.
- Cyclin D1 has limited ability to differentiate between neoplastic and non-neoplastic endometrial lesions.
- Sole reliance on Cyclin D1 for differentiating benign from malignant endometrial lesions is not credible.
Related Concept Videos
02:39Positive Regulator Molecules
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...